Acute phase clinical manifestation of COVID-19 is linked to long-COVID symptoms; A 9-month follow-up study

Introduction

As of this writing, more than 178 million cases of COVID-19 have been reported worldwide and more than 163 million have been recovered [1]. COVID-19 is recognized as a multi-organ disease with a broad spectrum of manifestations and there are increasing reports of prolonged effects after acute COVID-19 [2]. Some researchers define the term Post-Acute Sequelae of SARS-CoV-2 infection (PASC) for symptoms lasting more than 3 weeks after onset of the disease,and chronic symptoms of SARS-CoV-2 (CSSC) or long-COVID for those extending beyond 12 weeks [3, 4]. The prevalence of PASC and CSSCvary in different studies probably based on the severity of the acute symptoms, the duration of the follow-up, and other factors. In the study of Greenhalgh, T et al, it has beenreported 10% after 3 weeks [3]. In the post-acute COVID-19 US study performed 60 days after discharge, 6.7% of patients died,15.1% required readmission, and 32.6% of patients reported persistent or even new symptoms [5]. In another 6 months cohort study after discharge, excluding patients who were dead, readmitted,psychotic,demented, and immobile,76% of the patients had at least one residual symptom. In this study fatigue(63%), sleep difficulties(26%), hair loss (22%), and smell disorder(11%) were the most common residual symptoms [6]. Like several other respiratory viruses,COVID-19has neuroinvasive capacities. It may damage the CNS as a result of virus-induced neuro-immunopathology and/or virus-induced neuropathology. Other mechanisms of brain involvement may be due to the effect of the virus on other organs (such as the liver, kidneys, and hypoxia) and virus-induced coagulopathy. The psychosocial effects of the disease, such asisolation and distress about the disease and its consequences are other important issues after discharge[7]. Therefore, it is not surprising that neuropsychiatric symptoms are among the most common Post-Acutesymptoms. In one studyover 30% of hospitalized COVID-19patients exhibited cognitive problems, depression, and anxiety which persisted for months after discharge [7]. One month followinginfection there was a considerably high prevalence of insomnia (34-40%), depressivesymptoms (31-45%), anxiety symptoms (22-47%), Post Traumatic Stress Disorder (28%), and obsessive-compulsive symptoms (20%)[8, 9]. In a recent survey, Perils et al. found that 52.4% of COVID-19 patients had depressive symptoms according to Patient Health Questionnaire–9 (PHQ-9). In their study presence of headache was associated with greater probability of moderate or more severe depressive symptoms[10].

Neurocognitive symptoms are another category of post-COVID symptoms. In one study,34% of 279 hospitalized COVID-19 patients, reported memory loss and 28% described impaired concentration three months after discharge[11]. Other cognitive symptoms including impaired memory and receptive language and/or executive dysfunction have been reported[12]. New-onset dementia after hospitalization for COVID-19 was reported 2–3 times more common than what was observed after hospitalization for other medical conditions[13]. However, it is not yet clear which patients will develop PACS and CSSC symptoms, specifically chronic neuropsychiatric symptoms, after infection with COVID-19. A few efforts have been performed to find the association between clinical manifestations and sociodemographic factors of patients and neurocognitive sequelae of the COVID-19 disease in the future.For example, Woo,MS et al. studied 18 patients with mild to moderate COVID□19 disease with a mean age of 42 years and found that after around 85 days, over 75% of patients had difficulties in episodic memory, attention, and concentration,but these cognitive deficits were not associated with a history of fatigue, depression, hospitalization, treatment, viremia or acute inflammation[14]. However,in other studies, delirium as one of the most important neurocognitive symptoms during the acute phase of illness was suggested to contribute to long-term cognitive decline[15, 16]. Moreover, in other studies, the post-COVID manifestations were reported to be related to comorbidities and disease severity[17]. Most of the literature on predictors of long-COVID symptoms is whether subject to small sample size[14] or controversial results[15-17]. Therefore in this study, we tried to investigate the association of acute clinical manifestation of the COVID-19 and sociodemographic features of the patients, and the experience of long-COVID symptoms.We aimed to follow the patients we studied 9 months ago[18]. Neuropsychiatric symptoms were grouped into 3 distinct categories:anosmia and hypogeusia (olfactory symptoms); dizziness, headache, and limb force reduction (general constitutional-like neuropsychiatric symptoms); photophobia, mental state change, hallucination, vision and speech problem, seizure, stroke, and balance disturbance (specific neuropsychiatric symptoms or specific CNS type). There were also three non-neuropsychiatric clusters of symptoms: diarrhea and nausea (gastrointestinal symptoms); cough and dyspnea (respiratory symptoms); and fever and weakness (constitutional symptoms).The cluster of GI symptoms was closer to the neurological symptoms (specifically the ones with olfactory and general constitutional-like symptoms) [18].

Methods

Results

In the descriptive analysis easy fatigability 51.04%, was found to be the most common long COVID symptom followed by anxiety 38.54%, dyspnea 38.54%, and new headache 38.54%.Eighty-six (90%) patients showed at least onelong-COVID symptom in their follow-up. figure 1.

• Download figure
• Open in new tab

Figure 1: The frequency of long-COVID symptoms in the follow-up of 95 patients with history of COVID-19.

The persistent symptoms were then clustered based on similarity of symptoms and the symptoms clustered in the acute phase in the previous study. As you can see there were 8 main clusters: constitutional neuropsychiatric symptoms (including: Palpitation, Dizziness/Vertigo, Anxiety, Moodswing, Irritability, Newsuicidalidea, Paresthesia, Depression), dermatologic symptoms(including: Skinrash, Newhairloss), respiratory symptoms (including: Postexertionaldyspnea, Constantdyspnea, Dyspnea), GI symptoms (including: Constant.diarrhea/constipation, Constant.stomach.ache, Poor.appetite), Chronic fatigue syndrome (including: Sore throat, New headache, Constant musclepain, Constant joint pain, Easy.fatigue, Constant.fatigue, Constantweakness, Impairedconcentration/forgetfulness, Unrefreshing sleep, Tenderlymphnodes), specific neuropsychiatric symptoms (including: Auditoryhallucination, Visualhallucination, Visionimpairment, Visualdistortion, Doublevision), ENT symptoms (including: Constanthearingloss, Tinnitus). Constitutional neuropsychiatric symptoms are the most common reported cluster of symptoms 58.33% .figure 2.

• Download figure
• Open in new tab

Figure 2: The frequency of clusters of long-COVID symptoms in the follow-up of 95 patients with history ofCOVID-19.

Linear regression analysisin exploring sociodemographic predictors of chronic fatigue syndrome indicated that gender was a predictor of chronic fatigue syndrome, as this syndrome was more common in the female patients: 64% Female (median age = 49 [range 36 -86]) 36% Male (median age = 48.5 [range 39 -77];(F(1, 92) = -2.27, p = 0.02), while age was not(F(1, 92) = 1.27, p = 0.2 (n. s.)). Figure 3.

• Download figure
• Open in new tab

Figure 3. The relation of chronic fatigue syndrome (CFS) and age/ gender

The relation between clinical manifestations in the acute phase of COVID-19 and long COVID symptoms

In our previous study[18], we labeled the patients’ symptoms in six clusters: Constitutional-like Neuropsychiatric cluster (including dizziness, headache, and limb force reduction symptoms), Olfactory cluster(anosmia and hypogeusia symptoms), Constitutional cluster (including fever and weakness symptoms), Neuropsychiatric cluster (including photophobia, mental state change, hallucination, vision and speech problem, seizure, stroke, and balance disturbance symptoms), GI cluster(including diarrhea and nausea symptoms), and Respiratory cluster (including cough and dyspnea symptoms). Then, it was explored how the new persistent cluster symptoms reported by patients (long-COVID), which were classified in eight different classes in the previous section, are associated with early symptoms categories.To this end, multiple regression analysis was used to test if the early COVID symptoms could predict each of the new clusters or symptoms preserving within 9 months. The result of the general linear regression model indicated that the constitutional neuropsychiatric symptoms in the acute phase predictedthe chronic fatigue syndromein the future as long-COVID symptoms (R² =6.4%F(1, 93)= 2.529, p= 0.01).Further regression analysis showed that specific neuropsychiatric symptoms in the acute phase are associated with GI symptoms (R² = 6%, F(1,93)= 2.43, p = 0.01)in the future. Having specific neuropsychiatric symptoms in the acute phase is also a predictor of dermatologic disturbances in the future (R² = 8.5%, F(1,93)= 2.96, p = 0.003). Moreover, specific neuropsychiatric symptomspredicted the respiratory symptoms as long-COVID (R²= 9.8%, F(1,93)=3.19, p = 0.001). Respiratory symptoms in the acute phase predicted anosmia and dysgeusia symptoms in the future. They also marginally predictedolfactory symptoms in the acute phase of COVID-19, and finally those with constitutional and olfactory symptoms, in the acute phase of COVID-19,were predictors of ENT symptoms as long-COVID (R²=16%, F(2,93)=-1.913, p = 0.5, F(2,93)= 3.62, p = 0.0004 respectively).

There was no association between COVID-19 severity in the acute phase (admission status) and the number of long-COVID symptoms(F(1, 93) = 0.75, p = 0.45 (n.s.)). It was also no association between COVID-19 severity in the acute phase (admission status) and having CFS in the future as a long-COVID symptom (F(1,93) = -0.49, p = 0.62 (n.s.). However, the number of symptoms in the acute phase could predict having CFS in the future as long-COVID(F(1,93) = 2.76, p = 0.0068), Figure 4.

• Download figure
• Open in new tab

Figure 4. The relation of chronic fatigue syndrome (CFS) and the number of symptoms in the acute phase

• Download figure
• Open in new tab

Figure 5. The relation between the constitutional neuropsychiatric symptoms and follow-up MOCA score

Discussion

Our study was one of the few attempts to follow-up the patients within 9 months course after registering and clustering clinical manifestation of COVID-19 in the acute phase[18]. We found that there was an association between acute phase clinical manifestations of COVID-19 and long-COVID symptoms and cognitive sequelae in the future. However, we did not find any association between the severity of symptoms in the acute phase and long-COVID symptoms and cognitive sequelae in the future.

Long-COVID symptoms were very common among our patients. 90% of our patients reported physical or psychological symptoms within 9 months post-COVID. Easy fatigability 51.04 %, was found to be the most common long-COVID symptoms followed by anxiety 38.54 %, dyspnea 38.54 %, and new headache 38.54%. Constitutional neuropsychiatric symptoms were the most common cluster of symptoms 58.33% reported within the 9-month follow-up. Chronic fatigue syndrome was reported in 22.92% of patients. Our study is consistent with previous studies that reported a high prevalence of long-COVID symptoms in follow-ups [25]. For example, Sykes et al reported long-COVID symptoms in eighty-six percent of their follow-up patients[25]. Consistent with other studies[26], there was no association between the disease severity in the acute phase of COVID-19 and the risk of developing long-COVID in the future. However, we showed that these post-acute symptoms could last quite for a long time, up to 9 months while previous literature mainly followed COVID-19 patients for a maximumof 6 months[2, 25, 27]. Experiencing physical symptoms along with psychological and cognitive symptomsfor several months couldput a burden on people with a history of COVID-19. Moreover, having psychological, cognitive, and physical symptoms would also suggest a biopsychosocial underlying mechanism for long-COVID, not merely apsychological underlying mechanism. Some studies implied that long-COVID represents a miscellany of physical and psychological symptoms, like Persian gulf war illnessand it could be a post-traumatic syndrome[25]. However, we found that there wasan association between the symptom categories of acute clinical manifestation of COVID-19 and long-COVID symptoms and they were not just random miscellany of symptoms coming together which makes long-COVID as just a post-traumatic stress syndromeless probable[28]. We found that constitutional neuropsychiatric symptom categories were associated with having a lower MOCA score in the future; while the number of COVID-19 symptoms in the acute phase, the severity of COVID-19 presented by the status of admission, and the duration of COVID-19 symptoms in the acute phase were not. These findings show that the pattern of organ involvement in COVID-19 specifically in the acute phase would show how you would experience your long-COVID in the future. It seems that systemic inflammation, even when it is not severe could lead to cognitive impairment in the future if it involves neuroinvasion in the acute phase [29, 30]. Our findings were consistent with previous studies which reported an age-dependent cognitive decline in the follow-up of COVID-19 patients[31]. Among MOCA scores, we found that impaired delayed recall was mostly associated with having constitutional neuropsychiatric symptoms in the acute phase. In other studies, different cognitive sequelae such as apathy, executive dysfunction, reduction in global cognition were reported and GABAergic dysbalance have been proposed as the underlying mechanism for executive dysfunction [32].

We also found that neuropsychiatric involvement other than a cognitive decline in the acute phase was a good predictor of long-COVID in different organs in the future. Experiencing specific neuropsychiatric symptom categories in the acute phase was associated with specific GI, dermatologic, and respiratory symptoms in the future. Martina Sollina et al, in their study, showed that vascular inflammation could be the leading cause of long-lasting COVID symptoms [28]. It is not yet clear whether these organs share a similar receptor in their vasculature or other cellular structure.

We also found that those with respiratory symptomsin the acute phase were associated with longer anosmia and dysgeusia problems. So it seems that not all of the infected individuals would suffer from long olfactory problems, but it is more probable in those who experience COVID-19 with lung involvement.

Those with constitutional and olfactory symptoms, in the acute phase of COVID-19, were associated with ENT (tinnitus and hearing loss) symptoms in the future.

All of these could be explained by similar receptors in the vascular structure of different organs as a result of systemic inflammatory responses [28]. It could be a matter of future debate and exploration.

Being female, experiencingthe constitutional neuropsychiatric symptom categories in the acute phase, and having a higher number of symptoms in the acute phase could predict CFS in the future. This was consistent withother results in our study that the severity of the COVID -19 presented by admission status in the acute phase could not predict developing long-COVID in the future. It seems that it is also true for chronic fatigue syndrome and what is more important to predict the risk of CFS in the future is the pattern of organ involvement in the acute phase rather than the severity of the disease (low saturation, loss of consciousness, shock, admission status). It would suggest the mechanism of CFS is similar to other long-COVID symptoms. These findings are in line with previous studies [33]. Liam Townsend et al., also found that COVID persistent fatigue to be more common in females and is not associated with acute illness severity (admission status and laboratory inflammatory markers) [33]. One possible mechanism would be a state of chronic low-grade neuroinflammation followed by the disease [29]. COVID-19 can infect the brain leading to neuroinflammation [34]. Alternatively, it can cause inflammation in another part of the body, activating an innate immune response in the brain via humoral response and retrograde vagus nerve travel [30, 35]. Neuroinflammation can cause severe fatigue [36]. This will explain the association of constitutional neuropsychiatric symptoms in the acute phase and CFS in the future.

All in all, finding both physical and psychological long-COVID symptoms emphasizes the need for a multidisciplinary rehabilitation team in COVID-19 survivors.

However, our study was not without limitations. A number of patients from the original study who did not cooperate in the second study could change the current result. A small number of cases had full workup of paraclinical data and chest imaging in the electronic system of the hospital from the original study; therefore, finding an association between blood marker and long-COVID symptoms was not possible. Future studies to explore the association between symptom categories and inflammatory markers in the acute phase and long-COVID symptoms could shed new light on the underlying mechanism of the post-acute phase in people suffering from COVID-19.

Conclusion

Most of our patients experienced at least one physical, psychological or cognitive symptoms within 9 months following COVID-19. Easy fatigability, followed by headache, anxiety, and dyspnea were the most common long-COVID symptoms. There was an association between the acute presentation of COVID-19 and long-COVID symptoms in the follow-up, which was not related to disease severity. Having constitutional neuropsychiatric symptoms in the acute phase was associated with chronic fatigue syndrome, lower MOCA score, and poorer performance on delayed recall in future. Having specific neuropsychiatric symptoms in the acute phase was associated with dermatologic, GI, and respiratory symptoms in the future as long-COVID. These results might pave the way for finding the underlying mechanisms oflong-COVID and provide additional insight into possible candidate treatmentsfor COVID-19.

Declarations

Competing interests

All authors declare that they have no conflict of interest to disclose.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Availability of data and materials

The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

FSM, and ASJ contributed as first authors.

FSM, and ASJ: conceptualization and design of the manuscript; Ak, BS, SVS and SHRF: drafting of the manuscript; Ak, BS, SVS, SB, SN, MAD: reviewing the literature and writing the manuscript. Ak, BS, and SVS: the statistical analysis and methodology. SB, SN, MAD acquisition of the data; FSM, ASJ and SHRF were supervisions. All the authors: revising the paper for critically important intellectual content, and final approval of the version to be published; All authors contributed to editing the manuscript. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. SHRF is guarantor.